Sun Pharmaceutical Industries has launched generic versions of Daiichi Sankyo medicines, used in the treatment of high blood pressure, in the US market.
In a BSE filing, Sun Pharmaceutical Industries today said: “its wholly owned subsidiary has launched in US, the authorised generic versions for all strengths of Benicar, Benicar HCT, Azor and Tribenzor of Daiichi Sankyo Inc’’.
The four medicines are Olmesartan Medoxomil, Olmesartan Medoxomil-Hydrochlorothiazide, Amlodipine Besylate-Olmesartan Medoxomil and Amlodipine Besylate-Hydrochlorothiazide-Olmesartan Medoxomil tablets.
“The launch is pursuant to a distribution and supply agreement between Sun Pharma’s wholly owned subsidiary and Daiichi Sankyo Inc, which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US for a pre-determined period,” it added.
Quoting IMS Health data, Sun Pharma said Benicar, Benicar HCT, Azor and Tribenzor recorded US sales of approximately $2.5 billion for the 12 months ending August 31, 2016.
Shares of Sun Pharma were trading at Rs 745.05 apiece on the BSE, up 0.74 per cent from the previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.